Moreover, in the study by Eto et al [27], which involved 105 patients with stage II/III gastric carcinoma analysis demonstrated that the 3-year disease-free survival rate was 36.1 % in patients with PD-L1 overexpression and 64.7% in PD-L1-negative patients. This evidence concerns the gene CD274 and gastric carcinoma.